Exhibit 99.1

[LOGO of Antares Pharma, Inc.]

Contact Information
Dr. Roger Harrison        CEO and President                       (610) 458-6200
Lawrence M. Christian     CFO and Vice President - Finance        (610) 458-6200
Jay M. Green              Managing Director, Duncan Capital       (212) 581-5150

     ANTARES PHARMA ANNOUNCES A SECOND $2.0 MILLION PRIVATE EQUITY PLACEMENT

Exton, Pennsylvania - July 22, 2003 - Antares Pharma, Inc. (OTCBB: ANTR) today
announced that it has completed the second tranche of a planned $4.0 million
private placement of common equity. The second tranche of $2.0 million was under
the same terms as the equity placement announced on July 9, 2003, and was also
priced at the $1.00 value of Antares Pharma's shares as of the close of business
on July 3, 2003. The participants in this tranche of the financing include SCO
Capital Partners LLC, North Sound Legacy Funds, and Vertical Ventures
Investments LLC. SCO Securities LLC acted as the placement agent.

     Lawrence Christian, Chief Financial Officer of Antares Pharma, said, "This
equity placement provides further working capital needed to support our ongoing
operations and to secure additional technology license agreements. After the
completion of this sale of equity, we estimate our cash position, when combined
with our plans to further reduce our monthly cash burn, will provide operating
capital well into 2004."

About Antares Pharma

     Antares Pharma develops pharmaceutical delivery systems, including
needle-free and mini-needle injector systems and transdermal gel technologies.
These delivery systems are designed to improve both the efficiency of drug
therapies and the patient's quality of life. The Company currently distributes
its needle-free injector systems in more than 20 countries. In addition, Antares
Pharma conducts research and development with transdermal gel products and
currently has several products in clinical evaluation with partners in the US
and Europe. The Company is also conducting ongoing research to create new
products that combine various elements of the Company's technology portfolio.
Antares Pharma has corporate headquarters in Exton, Pennsylvania, with
manufacturing and research facilities in Minneapolis, Minnesota, and research
facilities in Basel, Switzerland.

     Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause
actual results to differ materially and which are identified from time to time
in the Company's reports filed with the U.S. Securities and Exchange Commission.
Antares Pharma claims the protection of the Safe Harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma's web site at www.antarespharma.com.
  Information included on the Company's website is not incorporated herein by
                            reference or otherwise.

                                  Page 1 of 1